ICUI Overview

ICU Medical, Inc. develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications. Its product portfolio includes ambulatory, syringe, and large volume IV pumps and safety software; dedicated and non-dedicated IV sets, needlefree IV connectors, peripheral IV catheters, and sterile IV solutions; closed system transfer devices and pharmacy compounding systems; as well as a range of respiratory, anesthesia, patient monitoring, and temperature management products. Its Infusion Therapy products include Clave needlefree products, Neutron, ClearGuard, and Tego. Its oncology products include ChemoLock Closed System Transfer Devices (CSTD) and Deltec GRIPPER non-coring needles for portal access. Its vascular access products include Safe-T Wing venipuncture and blood collection devices; Port-A-Cath implantable port, and Portex arterial blood sampling syringes. Its Tracheostomy products include Portex BLUselect PVC tracheostomy tubes.

Wall Street analysts forecast ICUI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ICUI is173.50 USD with a low forecast of 172.00 USD and a high forecast of 175.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

ICU Medical Inc revenue for the last quarter amounts to 540.70M USD, decreased -14.15

ICU Medical Inc. EPS for the last quarter amounts to -0.64 USD, decreased -34.02

ICU Medical Inc (ICUI) has 13000 emplpoyees as of March 02 2026.

Today ICUI has the market capitalization of 3.63B USD.